Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for...

Dr Tanuj Chawla and Dr Giovanni Selvaggi

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer ( Dr Tanuj Chawla and Dr Giovanni Selvaggi )

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and...

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates...

Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates in resected stage I-III colorectal cancer ( Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA )

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not...

Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure ( Prof Arthur Sun Myint - Clatterbridge Cancer Centre, Clatterbridge, UK )

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful...

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )

The placebo effect in oncology trials and the criteria for approving drugs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

The placebo effect in oncology trials and the criteria for approving drugs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Breast-conserving therapy may be option for multiple breast lesions

Dr Judy Boughey - Mayo Clinic, Rochester, USA

Breast-conserving therapy may be option for multiple breast lesions ( Dr Judy Boughey - Mayo Clinic, Rochester, USA )

ZUMA-7: Axi-cel is superior to standard of care across common prognostic...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR...

Dr Fred Locke - Moffitt Cancer Center, Tampa, USA

Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR and OS in r/r LBCL patients ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

ASH 2022: Multiple myeloma roundup

Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA

ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk...

Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )

More from ecancer